asciminib
Orphan DrugFDA Approved, EMA Approved
Description
Asciminib is the first specifically targeting ABL myristoyl pocket (STAMP) inhibitor. It provides a new mechanism of action for treating chronic myeloid leukemia, particularly beneficial for patients who have developed resistance to previous TKI therapies.
Indications & Therapeutic Use
Philadelphia chromosome-positive chronic myeloid leukemia
Linked Diseases:
chronic myeloid leukemia
C92.1D015464
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
asciminib
| Generic Name | asciminib |
| Brands | 1 brand available |
| Active Ingredient | asciminib hydrochloride |
| Drug Class | Philadelphia chromosome-positive chronic myeloid leukemia |
| Manufacturer | Novartis |
| Dosage Forms | Oral tablets, 20mg and 40mg |
| Medical Code | L01EA04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT02081378 |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes